Immatics to Raise $125 Million Through Underwritten Offering

Posted on by

Houston, Texas and Tuebingen, Germany, December 05, 2025 – (NASDAQ: IMTX, “Immatics” or the “Company”), a biopharmaceutical firm in clinical development and the global frontrunner in the precise targeting of PRAME, today announced its agreement to offer 12,500,000 ordinary shares at $10.00 each through an underwritten offering. The anticipated gross proceeds from this offering, prior to accounting for underwriting discounts and related expenses, are projected to be $125 million. The transaction is slated to finalize on December 8, 2025, pending the satisfaction of customary closing stipulations.  

Jefferies, Leerink Partners, and Cantor are acting as the joint book-running managers for this offering.

A registration statement pertinent to these securities was submitted to the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on April 3, 2025. This offering is being made exclusively by means of a prospectus supplement alongside an accompanying prospectus. Upon availability, complimentary copies of the definitive prospectus supplement and its accompanying prospectus concerning the offering may be obtained from:

  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com;
  • Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@leerink.com;
  • Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, e-mail: prospectus@cantor.com.

This press release does not constitute an offer to sell or a solicitation of an offer to purchase these securities, nor shall these securities be sold in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful without prior registration or qualification under the securities laws of that state or jurisdiction. All offers, solicitations to buy, or sales of securities will be executed in compliance with the registration mandates of the Securities Act of 1933, as amended.

About Immatics
Immatics is dedicated to creating a significant positive change in the lives of individuals battling cancer. We hold the top position globally in the precise targeting of PRAME, a marker found in over 50 different cancer types. Our advanced scientific methodologies and robust clinical pipeline establish the most comprehensive PRAME franchise, offering the broadest array of PRAME indications and therapeutic modalities, including TCR T-cell therapies and TCR bispecifics.

Forward-Looking Statements
Certain declarations within this press release might be categorized as forward-looking statements, encompassing those pertaining to the securities offering. Such forward-looking statements are contingent on various risks, uncertainties, and other elements that could lead to actual results deviating substantially from those expressed or implied therein. These forward-looking statements are founded upon estimations and assumptions which, despite being deemed reasonable by Immatics and its management, carry inherent uncertainties. New risks and uncertainties may materialize periodically, and it is not feasible to foresee all such risks and uncertainties. Factors that could cause actual outcomes to differ materially from current expectations include, but are not limited to, diverse factors beyond management’s influence, such as general economic conditions and other risks, uncertainties, and factors detailed in filings made with the SEC. Nothing presented in this press release should be construed as an assurance by any party that the forward-looking statements contained herein will be realized or that any of their anticipated results will be achieved. You are advised against placing undue reliance on forward-looking statements, as their validity extends only to the date they are made. Immatics assumes no obligation to revise these forward-looking statements.

For more information, please contact:

Press
Trophic Communications
Phone: +49 151 74416179

Immatics N.V. 
Jordan Silverstein
Strategic Lead
Phone: +1 346 319-3325
 

Attachment